{
    "name": "metreleptin",
    "comment": "Rx",
    "other_names": [
        "Myalept"
    ],
    "classes": [
        "Leptin Analogs"
    ],
    "source": "https://reference.medscape.com/drug/myalept-metreleptin-999894",
    "pregnancy": {
        "common": [
            "A program monitors outcomes in women exposed to MYALEPT during pregnancy; women who become pregnant during MYALEPT treatment are encouraged to enroll; patients or their physicians should call 1-855-669-2537 to enroll",
            "Available pharmacovigilance reports in pregnant women are insufficient to evaluate for any drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes; these reports describe similar adverse pregnancy outcomes as those documented in women with lipodystrophy",
            "Drug contains benzyl alcohol when reconstituted with BWFI; it contains no preservative when reconstituted with WFI; because benzyl alcohol is rapidly metabolized by a pregnant woman, benzyl alcohol exposure in the fetus is unlikely; however, adverse reactions have occurred in premature neonates and low birth weight infants who received intravenously administered benzyl alcohol-containing drugs; if therapy is needed during pregnancy, consider using preservative-free WFI when reconstituting",
            "Lipodystrophy in pregnancy can result in an increased rate of gestational diabetes, macrosomia, eclampsia, intrauterine growth retardation, intrauterine death, and miscarriage",
            "Effects on labor and delivery in pregnant women are unknown; in a published "
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In an animal reproduction study, no adverse developmental effects were observed with subcutaneous administration of drug to pregnant mice during organogenesis at doses 7-and 15-fold maximum recommended clinical dose, based on body surface area of a 20-and 60-kg patient, respectively",
                    "In a pre-and postnatal development study in mice, subcutaneous administration caused prolonged gestation and dystocia resulting in maternal death during parturition and lower survival of offspring in immediate postnatal period at doses starting approximately at maximum recommended clinical dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no available data on presence of drug in human milk; however, endogenous leptin is present in human milk; there are no available data on effects of drug on breastfed infant or effects on milk production",
            "Developmental and health benefits of breastfeeding should be considered along with motherâ€™s clinical need for therapy and any potential adverse effects on breastfed child from drug or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Neutralizing antibodies",
                    "description": [
                        "Antimetreleptin antibodies with neutralizing activity have been identified in patients treated with metreleptin",
                        "The consequences of these neutralizing antibodies are not well characterized but could include inhibition of endogenous leptin action and/or loss of efficacy",
                        "Severe infection and/or worsening metabolic control reported",
                        "Test for antimetreleptin antibodies with neutralizing activity in patients who develop severe infections or show signs suspicious for loss of efficacy during treatment"
                    ]
                },
                {
                    "type": "Lymphoma",
                    "description": [
                        "T-cell lymphoma has been reported in patients with acquired generalized lipodystrophy, both treated and not treated with metreleptin",
                        "Carefully consider the benefits and risks of treatment in patients with significant hematologic abnormalities and/or acquired generalized lipodystrophy"
                    ]
                },
                {
                    "type": "Myalept Risk Evaluation and Mitigation Strategy (REMS) Program",
                    "description": [
                        "Because of the risk for autoantibodies and lymphoma, prescribers must be certified with the Myalept REMS Program by enrolling in and completing training",
                        "Pharmacies must be certified with the program and only dispense metreleptin after receipt of the REMS prescription authorization form for each new prescription"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity, including urticaria and generalized rash",
                "General obesity not associated with congenital leptin deficiency; has not been shown to be effective in treating general obesity, and the development of antimetreleptin antibodies with neutralizing activity has been reported in obese patients treated with metreleptin"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "For SC injection only; instruct patients and caregivers on the proper SC injection technique (see Administration)",
                "Neutralizing antibody activity to leptin and/or metreleptin may develop, which could result in severe infections or loss of treatment effectiveness (see Black Box Warnings)",
                "T-cell lymphoma reported in patients with acquired generalized lipodystrophy, both treated and not treated with metreleptin (see Black Box Warnings)",
                "Dosage adjustments, including possible large reductions, of insulin or insulin secretagogue (eg, sulfonylurea, meglitinide derivatives) may be necessary in some patients to minimize the risk of hypoglycemia (see Dosage Modifications)",
                "Hypersensitivity reported; promptly discontinue if hypersensitivity occurs"
            ],
            "specific": [
                {
                    "type": "Benzoyl alcohol",
                    "description": [
                        "Contains benzyl alcohol when reconstituted with bacteriostatic water for injection",
                        "Reconstitute with preservative-free water for injection when used in neonates and infants",
                        "Benzoyl alcohol doses >99 mg/kg/day in neonates and low-birth-weight infants is associated with gasping syndrome",
                        "Gasping syndrome is characterized by CNS depression, metabolic acidosis, gasping respirations, and high levels of benzyl alcohol and its metabolites found in the blood and urine"
                    ]
                },
                {
                    "type": "Autoimmunity",
                    "description": [
                        "Leptin plays a role in immune system homeostasis",
                        "Acquired lipodystrophies are associated with autoimmune disorders (eg, autoimmune hepatitis, membranoproliferative glomerulonephritis)",
                        "Cases of progression of autoimmune hepatitis and membranoproliferative glomerulonephritis (associated with massive proteinuria and renal failure) were observed in some patients with acquired generalized lipodystrophy treated with metreleptin"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpropamide",
            "description": {
                "common": "chlorpropamide, metreleptin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of metreleptin with insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinide derivatives) may increase risk for hypoglycemia; may require lower dose of insulin or insulin secretagogue."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glimepiride",
            "description": {
                "common": "glimepiride, metreleptin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of metreleptin with insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinide derivatives) may increase risk for hypoglycemia; may require lower dose of insulin or insulin secretagogue."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glipizide",
            "description": {
                "common": "glipizide, metreleptin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of metreleptin with insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinide derivatives) may increase risk for hypoglycemia; may require lower dose of insulin or insulin secretagogue."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glyburide",
            "description": {
                "common": "glyburide, metreleptin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of metreleptin with insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinide derivatives) may increase risk for hypoglycemia; may require lower dose of insulin or insulin secretagogue."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin aspart",
            "description": {
                "common": "insulin aspart, metreleptin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of metreleptin with insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinide derivatives) may increase risk for hypoglycemia; may require lower dose of insulin or insulin secretagogue."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin detemir",
            "description": {
                "common": "insulin detemir, metreleptin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of metreleptin with insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinide derivatives) may increase risk for hypoglycemia; may require lower dose of insulin or insulin secretagogue."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin glargine",
            "description": {
                "common": "insulin glargine, metreleptin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of metreleptin with insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinide derivatives) may increase risk for hypoglycemia; may require lower dose of insulin or insulin secretagogue."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin glulisine",
            "description": {
                "common": "insulin glulisine, metreleptin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of metreleptin with insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinide derivatives) may increase risk for hypoglycemia; may require lower dose of insulin or insulin secretagogue."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin lispro",
            "description": {
                "common": "insulin lispro, metreleptin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of metreleptin with insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinide derivatives) may increase risk for hypoglycemia; may require lower dose of insulin or insulin secretagogue."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin NPH",
            "description": {
                "common": "insulin NPH, metreleptin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of metreleptin with insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinide derivatives) may increase risk for hypoglycemia; may require lower dose of insulin or insulin secretagogue."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin regular human",
            "description": {
                "common": "insulin regular human, metreleptin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of metreleptin with insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinide derivatives) may increase risk for hypoglycemia; may require lower dose of insulin or insulin secretagogue."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nateglinide",
            "description": {
                "common": "nateglinide, metreleptin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of metreleptin with insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinide derivatives) may increase risk for hypoglycemia; may require lower dose of insulin or insulin secretagogue."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "repaglinide",
            "description": {
                "common": "repaglinide, metreleptin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of metreleptin with insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinide derivatives) may increase risk for hypoglycemia; may require lower dose of insulin or insulin secretagogue."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolazamide",
            "description": {
                "common": "tolazamide, metreleptin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of metreleptin with insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinide derivatives) may increase risk for hypoglycemia; may require lower dose of insulin or insulin secretagogue."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolbutamide",
            "description": {
                "common": "tolbutamide, metreleptin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of metreleptin with insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinide derivatives) may increase risk for hypoglycemia; may require lower dose of insulin or insulin secretagogue."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Headache",
            "percent": "13"
        },
        {
            "name": "Hypoglycemia",
            "percent": "13"
        },
        {
            "name": "Decreased weight",
            "percent": "13"
        },
        {
            "name": "Abdominal pain",
            "percent": "10"
        },
        {
            "name": "Arthralgia",
            "percent": "8"
        },
        {
            "name": "Dizziness",
            "percent": "8"
        },
        {
            "name": "Ear infection",
            "percent": "8"
        },
        {
            "name": "Fatigue",
            "percent": "8"
        },
        {
            "name": "Nausea",
            "percent": "8"
        },
        {
            "name": "Ovarian cyst",
            "percent": "8"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "8"
        },
        {
            "name": "Anemia",
            "percent": "6"
        },
        {
            "name": "Back pain",
            "percent": "6"
        },
        {
            "name": "Diarrhea",
            "percent": "6"
        },
        {
            "name": "Paresthesia",
            "percent": "6"
        },
        {
            "name": "Proteinuria",
            "percent": "6"
        },
        {
            "name": "Pyrexia",
            "percent": "6"
        },
        {
            "name": "Antibodies with neutralizing activity",
            "percent": "6"
        },
        {
            "name": "Injection site erythema and urticaria",
            "percent": "4"
        },
        {
            "name": "Incorrect dose administered",
            "percent": null
        },
        {
            "name": "accidental overdose",
            "percent": null
        },
        {
            "name": "Injection",
            "percent": null
        },
        {
            "name": "site reaction",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "inflammation",
            "percent": null
        },
        {
            "name": "hyperpigmentation",
            "percent": null
        }
    ]
}